Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.
EP. 1: Defining Germline Sequencing and Incidental Germline Findings
Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.
EP. 2: Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling
Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.
EP. 3: Experience with Interpreting Somatic Reports
A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.
EP. 4: Identification of Patients for Germline Testing
The panel of experts provide insight on how they identify patients for germline testing.
EP. 5: Role of ctDNA in Germline Testing
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.
EP. 6: Operational Processes and Challenges
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer